Notably, the pan-CLK DYRK inhibitors lorecivivint (NCT04520607) and cirtuvivint (NCT05084859) have entered clinical trials for the treatment of knee osteoarthritis and cancer, respectively. This evidence concerns the gene CLK1 and cancer.